BioPharmSignal logoBioPharmSignal

Biotech News

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Immix Biopharma (IMMX)Immix BiopharmaClinical readout

- Oral presentation Sunday, December 7, at ASH 2025 -

LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that Phase 1/2 interim results from its U.S. NXC-201 NEXICART-2 trial in...

Related news

RVMDRevolution Medicines2026-06-23 12:00 EST

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

MGNXMacroGenics2026-07-23 20:01 EST

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

RVMDRevolution Medicines2026-07-02 12:00 EST

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

LEGNLegend Biotech Corporation2026-06-15 12:00 EST

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

IMMXImmix Biopharma2026-08-04 14:15 EST

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

GSKGSK plc2026-07-28 11:00 EST

GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China

LYELLyell Immunopharma2026-06-08 10:00 EST

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

View all latest news

Immix Biopharma

Immix Biopharma is a biotechnology company focused on immune-driven therapies and oncology programs. Its strategy centers on translating immune biology into targeted treatment options.

Recent company news

IMMXImmix Biopharma2026-08-04 14:15 EST

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

IMMXImmix Biopharma2026-05-22 22:15 EST

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-05-22 17:15 EST

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-05-21 11:30 EST

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-05-21 11:30 EST

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

Stock data

Close
13.66 USD
Market cap
595.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States